Literature DB >> 34304365

Characterization of the gut microbiota in patients with primary sclerosing cholangitis compared to inflammatory bowel disease and healthy controls.

Samaneh Ostadmohammadi1, Masoumeh Azimirad1, Hamidreza Houri1, Kaveh Naseri1, Ehsan Javanmard1, Hamed Mirjalali1, Abbas Yadegar2, Amir Sadeghi3, Hamid Asadzadeh Aghdaei4, Mohammad Reza Zali5.   

Abstract

BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease. Its etiology remains largely unknown, although frequent concomitant inflammatory bowel disease (IBD) hints towards common factors underlying intestinal and bile duct inflammation. Herein, we aimed to explore the relative abundance of fecal microbiota in PSC-IBD patients compared to IBD-only subjects and controls. METHODS AND
RESULTS: We included 14 PSC-IBD patients, 12 IBD-only patients, and 8 healthy controls (HCs). A quantitative real-time PCR (qPCR) assay was used to determine a selection of bacterial phyla, families, and genera. Relative abundance of taxa showed that Bacteroidetes was the most abundant phylum among the patients with PSC-IBD (29.46%) and also HCs (39.34%), whereas the bacterial species belonging to the phylum Firmicutes were the most frequent group in IBD-only subjects (37.61%). The relative abundance of the Enterobacteriaceae family in fecal samples of PSC-IBD patients was similar to those with IBD-only, which was significantly higher than HCs (p value = 0.031), and thus, could be used as a PSC-IBD or IBD-only associated microbial signature.
CONCLUSIONS: Our findings showed that intestinal microbiota composition in PSC-IBD patients was completely different from that of IBD-only patients. Further studies using large-scale cohorts should be performed to better describe the contribution of the gut microbiota to PSC pathogenesis with underlying IBD.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Gut microbiota; Inflammatory bowel disease; Primary sclerosing cholangitis; Real-time PCR; Ulcerative colitis

Year:  2021        PMID: 34304365     DOI: 10.1007/s11033-021-06567-8

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  35 in total

1.  Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease.

Authors:  Kirsten Boonstra; Karel J van Erpecum; Karin M J van Nieuwkerk; Joost P H Drenth; Alexander C Poen; Ben J M Witteman; Hans A R E Tuynman; Ulrich Beuers; Cyriel Y Ponsioen
Journal:  Inflamm Bowel Dis       Date:  2012-03-08       Impact factor: 5.325

Review 2.  Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review.

Authors:  Kirsten Boonstra; Ulrich Beuers; Cyriel Y Ponsioen
Journal:  J Hepatol       Date:  2012-01-13       Impact factor: 25.083

3.  A revised natural history model for primary sclerosing cholangitis.

Authors:  W R Kim; T M Therneau; R H Wiesner; J J Poterucha; J T Benson; M Malinchoc; N F LaRusso; K D Lindor; E R Dickson
Journal:  Mayo Clin Proc       Date:  2000-07       Impact factor: 7.616

4.  Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis.

Authors:  R Olsson; A Danielsson; G Järnerot; E Lindström; L Lööf; P Rolny; B O Rydén; C Tysk; S Wallerstedt
Journal:  Gastroenterology       Date:  1991-05       Impact factor: 22.682

Review 5.  Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.

Authors:  John E Eaton; Jayant A Talwalkar; Konstantinos N Lazaridis; Gregory J Gores; Keith D Lindor
Journal:  Gastroenterology       Date:  2013-07-01       Impact factor: 22.682

6.  Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease.

Authors:  Aoibhlinn O'Toole; Alaa Alakkari; Denise Keegan; Glen Doherty; Hugh Mulcahy; Diarmuid O'Donoghue
Journal:  Clin Gastroenterol Hepatol       Date:  2011-11-15       Impact factor: 11.382

7.  Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study.

Authors:  J H Tabibian; E Weeding; R A Jorgensen; J L Petz; J C Keach; J A Talwalkar; K D Lindor
Journal:  Aliment Pharmacol Ther       Date:  2013-02-05       Impact factor: 8.171

8.  Characterization of Intestinal Microbiota in Ulcerative Colitis Patients with and without Primary Sclerosing Cholangitis.

Authors:  D Kevans; A D Tyler; K Holm; K K Jørgensen; M H Vatn; T H Karlsen; G G Kaplan; B Eksteen; D Gevers; J R Hov; M S Silverberg
Journal:  J Crohns Colitis       Date:  2015-11-02       Impact factor: 9.071

9.  A novel prognostic model for transplant-free survival in primary sclerosing cholangitis.

Authors:  Elisabeth M de Vries; Junfeng Wang; Ronald B Geskus; Cyriel Y Ponsioen; Kate D Williamson; Mariska M Leeflang; Kirsten Boonstra; Rinse K Weersma; Ulrich Beuers; Roger W Chapman
Journal:  Gut       Date:  2017-07-24       Impact factor: 23.059

10.  Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis.

Authors:  Jimmy Z Liu; Johannes Roksund Hov; Trine Folseraas; Eva Ellinghaus; Simon M Rushbrook; Nadezhda T Doncheva; Ole A Andreassen; Rinse K Weersma; Tobias J Weismüller; Bertus Eksteen; Pietro Invernizzi; Gideon M Hirschfield; Daniel Nils Gotthardt; Albert Pares; David Ellinghaus; Tejas Shah; Brian D Juran; Piotr Milkiewicz; Christian Rust; Christoph Schramm; Tobias Müller; Brijesh Srivastava; Georgios Dalekos; Markus M Nöthen; Stefan Herms; Juliane Winkelmann; Mitja Mitrovic; Felix Braun; Cyriel Y Ponsioen; Peter J P Croucher; Martina Sterneck; Andreas Teufel; Andrew L Mason; Janna Saarela; Virpi Leppa; Ruslan Dorfman; Domenico Alvaro; Annarosa Floreani; Suna Onengut-Gumuscu; Stephen S Rich; Wesley K Thompson; Andrew J Schork; Sigrid Næss; Ingo Thomsen; Gabriele Mayr; Inke R König; Kristian Hveem; Isabelle Cleynen; Javier Gutierrez-Achury; Isis Ricaño-Ponce; David van Heel; Einar Björnsson; Richard N Sandford; Peter R Durie; Espen Melum; Morten H Vatn; Mark S Silverberg; Richard H Duerr; Leonid Padyukov; Stephan Brand; Miquel Sans; Vito Annese; Jean-Paul Achkar; Kirsten Muri Boberg; Hanns-Ulrich Marschall; Olivier Chazouillères; Christopher L Bowlus; Cisca Wijmenga; Erik Schrumpf; Severine Vermeire; Mario Albrecht; John D Rioux; Graeme Alexander; Annika Bergquist; Judy Cho; Stefan Schreiber; Michael P Manns; Martti Färkkilä; Anders M Dale; Roger W Chapman; Konstantinos N Lazaridis; Andre Franke; Carl A Anderson; Tom H Karlsen
Journal:  Nat Genet       Date:  2013-04-21       Impact factor: 38.330

View more
  2 in total

Review 1.  The effects of probiotic and synbiotic supplementation on inflammation, oxidative stress, and circulating adiponectin and leptin concentration in subjects with prediabetes and type 2 diabetes mellitus: a GRADE-assessed systematic review, meta-analysis, and meta-regression of randomized clinical trials.

Authors:  Kaveh Naseri; Saeede Saadati; Farahnaz Ghaemi; Damoon Ashtary-Larky; Omid Asbaghi; Amir Sadeghi; Reza Afrisham; Barbora de Courten
Journal:  Eur J Nutr       Date:  2022-10-14       Impact factor: 4.865

2.  Is primary sclerosing cholangitis with inflammatory bowel disease different between patients in the East and West?

Authors:  Yong Eun Park
Journal:  Intest Res       Date:  2022-04-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.